Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Dynavax Technologies Corporation is actively prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions, reflecting an active pipeline of biological and pharmaceutical innovations undergoing review. These actions are distributed across 2 distinct art units, which indicates that the technical subject matter is being evaluated by 2 different specialized groups. This requires the legal team to address the specific examination standards and technical requirements of both art units.
The examination process involves 4 distinct examiners, meaning that each of the 4 pending office actions is being handled by a different individual. BLUMEL, BENJAMIN P is the busiest examiner for this portfolio, currently managing 1 pending office action. Since the number of examiners is equal to the number of pending actions, the workload is evenly distributed across the assigned staff. Practitioners must manage 4 separate technical dialogues, each with a different examiner, while navigating the specific standards of the 2 art units involved in the prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| FOLEY, SHANON A | 1 | 73.3% | +18.1% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18267083 | METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM | SITTON, JEHANNE SOUAYA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838947 | IMMUNOGENIC COMPOSITIONS COMPRISING A RECOMBINANT NEURAMINIDASE AND CpG OLIGONUCLEOTIDE ADJUVANT, AND USES THEREOF | BLUMEL, BENJAMIN P | — |
| 18723407 | IMMUNOGENICITY OF A CPG-ADJUVANTED HERPES ZOSTER VACCINE | SALVOZA, M FRANCO G | — |
| 18592811 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) | FOLEY, SHANON A | — |
| 18267083 | METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM | SITTON, JEHANNE SOUAYA | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838947 | IMMUNOGENIC COMPOSITIONS COMPRISING A RECOMBINANT NEURAMINIDASE AND CpG OLIGONUCLEOTIDE ADJUVANT, AND USES THEREOF | BLUMEL, BENJAMIN P | — | §103DP | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18723407 | IMMUNOGENICITY OF A CPG-ADJUVANTED HERPES ZOSTER VACCINE | SALVOZA, M FRANCO G | — | §103 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18629809 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18592811 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST VARIANTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) | FOLEY, SHANON A | — | §103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18267083 | METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN COMPOSITIONS COMPRISING ALUM | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial